Medical Equipments, Pharmaceuticals And Personal Care Products Tenders

Conclusion of a Non-Exclusive Discount Agreement According to § 130A Para. 8 Sgb V for the Active Ingredient Ambroxol, Atc R05cb06 for the Period February 1St, 2023 - January 31St, 2025

Conclusion of a Non-Exclusive Discount Agreement According to § 130A Para. 8 Sgb V for the Active Substance Flupentixol (Exclusively Parenteral Dosage Form), Atc N05af01 for the Period February 1St, 2023 - January 31St, 2025

Conclusion of a Non-Exclusive Discount Agreement According to § 130A Para. 8 Sgb V for the Active Substance Methocarbamol (Only 1500 Mg), Atc M03ba03 for the Period February 1St, 2023 - January 31St, 2025

Open House Drug Rebate Contracts Trientine, Atc A16ax12

Open House Drug Rebate Contracts Buserelin, Atc L02ae01

Conclusion of a Non-Exclusive Discount Agreement According to § 130A Para. 8 Sgb V for the Active Ingredient Secucinumab, Atc L04ac10 for the Period February 1St, 2023 - January 31St, 2025

Conclusion of a Non-Exclusive Discount Agreement According to § 130A Para. 8 Sgb V for the Active Ingredient Peg-Epoetin Beta, Atc B03xa03 for the Period February 1St, 2023 - January 31St, 2025

Conclusion of a Non-Exclusive Discount Agreement in Accordance with Section 130A Paragraph 8 Sgb V for the Active Ingredient Lipegfilgrastim, Atc L03aa14 for the Period February 1St, 2023 - January 31St, 2025

Conclusion of a Non-Exclusive Discount Agreement According to § 130A Para. 8 Sgb V for the Active Ingredient Ranolazine, Atc C01eb18 for the Period February 1St, 2023 - January 31St, 2025

Conclusion of a Non-Exclusive Discount Agreement According to § 130A Para. 8 Sgb V for the Active Ingredient Ciclospiron, Atc L04ad01 for the Period February 1St, 2023 - January 31St, 2025